Imidafenacin

Imidafenacin

Clinical data
Routes of administration	By mouth
ATC code	G04BD14 ( WHO )
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide
CAS Number	170105-16-5  Y
PubChem CID	6433090
ChemSpider	4938278  N
UNII	XJR8Y07LJO
ChEMBL	ChEMBL53366  N
CompTox Dashboard (EPA)	DTXSID00870104
ECHA InfoCard	100.216.585
Chemical and physical data
Formula	C20H21N3O
Molar mass	319.408 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N
InChI InChI=1S/C20H21N3O/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,13,15H,12,14H2,1H3,(H2,21,24) N Key:SQKXYSGRELMAAU-UHFFFAOYSA-N N
NY  (what is this?)    (verify)

Imidafenacin (INN) is a urinary antispasmodic of the anticholinergic class. ^[1] It is used for the treatment of urinary incontinence and related bladder issues, especially in patients with benign prostatic hyperplasia or who have had prostate surgery. Unlike most related drugs, it is orally active but still shows a rapid onset of action, which makes it more convenient to administer. ^{[2] [3] [4]}

References

1. Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2007). "Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland". Arzneimittelforschung. 57 (2): 92–100. doi:10.1055/s-0031-1296589. PMID   17396619. S2CID   21636454.
2. Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Grossmann NC, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, König F, Roehrborn CG, Katayama S, Rajwa P, Hajebrahimi S, Shariat SF. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2022 Jul;8(4):1072-1089. doi : 10.1016/j.euf.2021.08.011 PMID   34563481
3. Su YT, Chen HL, Teoh JY, Chan VW, Wu WJ, Lee HY. Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients - a network meta-analysis. BMC Urol. 2023 Oct 3;23(1):154. doi : 10.1186/s12894-023-01327-1 PMID   37789333
4. Lee JH, Goh HJ, Lee K, Choi DW, Lee KM, Kim S. Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial. Investig Clin Urol. 2024 Sep;65(5):466-472. doi : 10.4111/icu.20240129 PMID   39249919